In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- Alpha Beta T-cell and B-cell depleted allogeneic transplantation followed by Blinatumomab therapy for high-risk B-Acute Lymphoblastic Leukemia pilot study
- Blinatumomab bridging therapy in high-risk B-ALL clinical trial
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Clinical Trials - Diseases by specialty group
Lymphoma 18
-
Protocol ID
- Associated disease
- Title
-
CHOP-ALPHABETA
- Non-Hodgkin's Lymphoma
- Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transplantation with a/b T Cell and B Cell Depletion for Patients with Hematologic Malignancies
-
COG-AALL1231
- Non-Hodgkin's Lymphoma
- A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
-
COG-AALL1731
- Non-Hodgkin's Lymphoma
- A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
-
COG-AALL1732
- Non-Hodgkin's Lymphoma
- A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
-
COG-ACCL1333
- Non-Hodgkin's Lymphoma
- A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-Asparaginase
-
COG-ADVL1412
- Non-Hodgkin's Lymphoma
- A Phase 1/2 Study of Nivolumab (Ind# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
-
COG-ADVL1414
- Non-Hodgkin's Lymphoma
- A Phase 1 Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
-
COG-ALTE11C1
- Non-Hodgkin's Lymphoma
- Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
-
COG-ANHL12P1
- Non-Hodgkin's Lymphoma
- A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117
-
COG-APEC1621A
- Non-Hodgkin's Lymphoma
- NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
-
COG-APEC1621B
- Non-Hodgkin's Lymphoma
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations
-
COG-APEC1621D
- Non-Hodgkin's Lymphoma
- NCI-COG PEDIATRIC MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors
-
COG-APEC1621E
- Non-Hodgkin's Lymphoma
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Selumetinib (Azd6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
-
COG-APEC1621F
- Non-Hodgkin's Lymphoma
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
-
COG-APEC1621H
- Non-Hodgkin's Lymphoma
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
-
COG-APEC1621I
- Non-Hodgkin's Lymphoma
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
-
COG-APEC1621K
- Non-Hodgkin's Lymphoma
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations
-
COG-APEC1621SC
- Non-Hodgkin's Lymphoma
- NCI - COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?